Epimmune and Anosys Announce Merger

In a move to create a combined company focused on the field of immunotherapeutics and products for the treatment of cancer and infectious diseases, Epimmune, Inc. (San Diego, CA, USA), has agreed to merge with privately-held Anosys (Menlo Park, CA, USA). The combined company will be headquartered in San Diego, with additional manufacturing facilities in Menlo Park (CA) and Evry, France.

Epimmune is focused on the development of pharmaceutical products using multiple epitopes to specifically activate the body's immune system. These critical signaling molecules stimulate the T cell arm of the immune system to respond to specific regions of cancer cells or infectious agents. Epimmune's drug candidates are designed to treat disease by stimulating the body's immune system to respond aggressively to infections such as HIV, hepatitis B and C viruses, and tumors such as breast, colon, lung, and prostate.

Anosys is developing therapeutic vaccines for the treatment of cancer and infectious and autoimmune diseases. These are based on a pioneering approach using exosomes from immune cells, which contain the key components required to activate the major innate and cellular immune responses necessary to fight disease. Exosomes can be genetically engineered to express a variety of proteins on their surface that can be used to generate monoclonal antibodies and for targeting of proteins to tissues and vaccines.





Related Links:
Epimmune
Anosys